Desktop Broker TV

Biotherapeutics company, CSL Limited (ASX:CSL), reported its half year earnings today, beating forecasts, and the market has responded positively.

For the six months, CSL reported a 19% increase in revenue to US$7,183 million, as well as a 10% lift in net profit after tax before amortisation in constant currency to US$1,957 million. Citi were expecting NPAT of US$1,795 million.

CSL’s earnings were partly driven by a five-month contribution from Vifor Pharma, as well as impressive sales growth and record levels of plasma collections.

CSL have lifted its interim dividend by 2.9% to US$1.07 per share.

And management reaffirmed its guidance for FY2023 NPAT in the range of US$2.7 billion to US$2.8 billion at constant currency.

CSL’s share price has been on the rise today, currently trading 0.6% higher at AU$306.88, at the time of recording.